Clinical trials · New York
Multiple myeloma clinical trials in New York
We’re tracking 90 recruiting multiple myeloma studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
New York, New YorkAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Buffalo, New YorkAges 12 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05201781RecruitingPhase 4
Long-term follow-up for people previously treated with cilta-cel
This study follows people over time who previously received cilta-cel in a Janssen-sponsored clinical trial. It helps doctors learn about how well the treatment works and how safe it is in the long run.
Buffalo, New YorkAges 18 years+ - NCT05932680RecruitingPhase 2
Continue teclistamab for a limited time in responding patients
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
New York, New YorkAges 18 years+ - NCT06083922RecruitingPhase 2
CyBorD plus Daratumumab for kidney disease caused by abnormal proteins
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
New York, New YorkAges 18 years+ - NCT06338150Recruiting
Precision medicine study for relapsed multiple myeloma
This study looks at your tumor sample to learn more about your multiple myeloma and find the best treatment for you. It does not give you a new drug, but uses your standard biopsy to help guide your care.
New York, New YorkAges 18 years+ - NCT06500884RecruitingPhase 2
Preventing mouth problems from GPRC5D therapy in myeloma
This study tests a preventive treatment for mouth or taste problems that can be caused by a newer type of multiple myeloma therapy. It aims to help people who have already tried several standard treatments and whose disease is still active.
New York, New YorkAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07149857RecruitingPhase 2
A study of CAR-T therapy for newly diagnosed multiple myeloma
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
New York, New YorkAges 18–80 - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Commack, New YorkAges 18 years+ - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Buffalo, New YorkAges 2 months+ - NCT00582621Recruiting
Family history study to support genetic testing research
This study collects family and medical history to better understand inherited causes of blood cancers (like lymphoma) and related conditions. It may help researchers build genetic findings that could improve how families understand their risk and future care.
Rockville Centre, New YorkAges Any age - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
New York, New YorkAges Any age - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Glens Falls, New YorkAges 19–110 - NCT02693535RecruitingPhase 2
Match FDA cancer drugs to a tumor gene change
This trial tests FDA-approved cancer medicines in people with advanced cancer whose tumor has a specific gene or protein abnormality. It tries to see whether targeting that tumor “fingerprint” can help when standard treatments no longer work.
New Hyde Park, New YorkAges 12 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
New York, New YorkAges 18 years+
Multiple myeloma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 8 studies
- Mount Sinai Health System · 7 studies
- Weill Cornell Medicine · 4 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Roswell Park Cancer Institute · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Multiple myeloma trials in other states
Common questions
- Are there multiple myeloma clinical trials in New York?
- Yes. We're currently tracking 90 recruiting multiple myeloma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.